[
  {
    "ts": null,
    "headline": "Behind The Volatility Of Vera Therapeutics",
    "summary": "Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may impact its potential.",
    "url": "https://finnhub.io/api/news?id=3ca0beda0e3e68f7a8c3b66b732d04bbdf5f5d5bc0dd0e47d506761c4cafd9c9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753606163,
      "headline": "Behind The Volatility Of Vera Therapeutics",
      "id": 136100475,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may impact its potential.",
      "url": "https://finnhub.io/api/news?id=3ca0beda0e3e68f7a8c3b66b732d04bbdf5f5d5bc0dd0e47d506761c4cafd9c9"
    }
  }
]